Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2020

Research By Markets adds Market Research Report - Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2020

For detailed information:

Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2020


Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2020, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 10, 24, 22, 5, 121, 38 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 35 and 10 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
1st Bio Therapeutics Inc
AB Science SA
Above and Beyond Concierge Therapeutics LLC
AC Immune SA
Aclipse One Inc
AcuraStem Inc
Adare Pharmaceuticals Inc
Affichem SA
AgoneX Biopharmaceuticals Inc
AI Therapeutics
AL-S Pharma AG
Alexion Pharmaceuticals Inc
AlphaCognition Inc
Alsonex Pty Ltd
Amicogen Inc
Amylyx Pharmaceutical Corp
Anavex Life Sciences Corp
Anelixis Therapeutics LLC
Anida Pharma Inc
Anima Biotech Inc
Ankar Pharma SL
Annexon Inc
Apic Bio Inc
Apogenix AG
Applied Genetic Technologies Corp
Aquilus Pharmaceuticals Inc
Aquinnah Pharmaceuticals Inc
ArmaGen Inc
ArunA Biomedical Inc
Asahi Kasei Pharma Corp
Asdera LLC
Astellas Pharma Inc
Athira Pharma Inc
Autophagy Neurotherapeutics Inc
Avanir Pharmaceuticals Inc
AveXis Inc
Axovant Gene Therapies Ltd
AZTherapies Inc
Bach Pharma Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Biorchestra Ltd
Bloom Science Inc
BrainStorm Cell Therapeutics Inc
Bruschettini Srl
Calico LLC
CavoGene LifeSciences
Cellenkos Inc
Cerion LLC
Chaperone Therapeutics Inc
Chemigen LLC
Chiesi Farmaceutici SpA
CholesteniX Ltd
Chronos Therapeutics Ltd
Chugai Pharmaceutical Co Ltd
Clene Nanomedicine Inc
Cogentis Therapeutics Inc
Collaborative Medicinal Development LLC
Constant Therapeutics LLC
Corcept Therapeutics Inc
Corestem Inc
CSPC NBP Pharmaceutical Co Ltd
Curatis AG
CuroNZ Ltd
Daiichi Sankyo Co Ltd
Denali Therapeutics Inc
Disarm Therapeutics Inc
Eikonizo Therapeutics Inc
Eisai Co Ltd
Elysium Health Inc
Emerald Health Sciences Inc
Enzerna Biosciences LLC
Eolo Pharma
Epigen Biosciences Inc
Everfront Biotech Inc
Exicure Inc
Gemac SA
Gene Therapy Research Institution Co Ltd
Genentech Inc
Generoath Co Ltd
Genervon Biopharmaceuticals LLC
GeNeuro SA
Genuv Inc
Gilead Sciences Inc
Glialogix Inc
GlyTag LLC
GNT Pharma Co Ltd
Grifols SA
Guangzhou Magpie Pharmaceutical Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Herantis Pharma Plc
Immunity Pharma Ltd
Implicit Bioscience Ltd
ImStar Therapeutics Inc
Inmune Bio Inc
Ionis Pharmaceuticals Inc
Iron Horse TherapeuticsInc
Junaxo Inc
K Pharma Inc
K-Pax Pharmaceuticals Inc
Kadimastem Ltd
Keapstone Therapeutics Ltd
Klogene Therapeutics Inc
Knopp Biosciences LLC
Kringle Pharma Inc
Kyorin Pharmaceutical Co Ltd
Kyowa Kirin Co Ltd
Lascco SA
Lauren Sciences LLC
LifeSplice Pharma LLC
Locana Inc
Maas Biolab
MedDay SA
MeiraGTx Holdings Plc
Meta-IQ ApS
MetVital Inc
MimeTech Srl
Miragen Therapeutics Inc
Mitoconix Bio Ltd
MitoDys Therapeutics Ltd
Mitsubishi Tanabe Pharma Corp
NeuExcell Therapeutics Inc
Neuracle Science Co Ltd
Neurimmune Holding AG
Neurodegeneration Therapeutics Inc
Neuroplast BV
Neuropore Therapies Inc
NeuroSense Therapeutics Ltd
Neurotune AG
New Biotic Inc
Novartis AG
NuNerve Pty Ltd
OptiKira LLC
Orion Corp
Orphazyme A/S
Orpheris Inc
Oxford BioMedica Plc
Passage Bio Inc
Pfizer Inc
Pharnext SA
Plex Pharmaceuticals Inc
Priavoid GmbH
Prilenia Therapeutics Development Ltd
ProMIS Neurosciences Inc
Prothena Corp Plc
Prous Institute for Biomedical Research SA
PTC Therapeutics Inc
Q Therapeutics Inc
QurAlis Corp
Ra Pharmaceuticals Inc
Rapa Therapeutics LLC
Relmada Therapeutics Inc
Retrotope Inc
Revalesio Corp
Sangamo Therapeutics Inc
Seneca Biopharma Inc
Shinkei Therapeutics LLC
Spedding Research Solutions SAS
Stealth BioTherapeutics Corp
Suzhou Auzone Biological Technology Co Ltd
Talon Pharmaceutical Services Inc
Thera Neuropharma Inc
Theragen Etex Co Ltd
Theratome Bio Inc
TikoMed AB
Tolerion Inc
Tranquis Therapeutics Inc
Treeway BV
Treventis Corp
Trucode Gene Repair Inc
Ultragenyx Pharmaceutical Inc
UniQure NV
Verge Genomics Inc
Voyager Therapeutics Inc
Wave Life Sciences Ltd
Xalud Therapeutics Inc
Xcelthera INC
Xonovo Inc
Yooyoung Pharm Co Ltd
Yumanity Therapeutics
Zhittya Genesis Medicine Inc
ZZ Biotech LLC

For queries regarding this report:

Contact Us:
Sales Desk
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via *Market Research News is a part of Research By Markets.